Free Trial

Curaleaf (OTCMKTS:CURLF) Shares Gap Down - Should You Sell?

Curaleaf logo with Medical background

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $0.84, but opened at $0.80. Curaleaf shares last traded at $0.83, with a volume of 45,374 shares.

Curaleaf Price Performance

The company has a 50-day moving average of $0.87 and a 200-day moving average of $1.13. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.70 and a current ratio of 1.41. The stock has a market cap of $543.97 million, a price-to-earnings ratio of -2.65 and a beta of 0.59.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Curaleaf had a negative net margin of 17.37% and a negative return on equity of 14.12%. As a group, equities research analysts predict that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.

About Curaleaf

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Rising Stocks You’ll Want on Your Watchlist
Trillions in Defense Spending—3 Disruptive Stocks Set to Double
The Next Palantir? AI-Defense Stock Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines